Compounds & interventions

Gene therapy

Medicine & Biotech · covered by 27 outlets this week · tracked since 2026-10-27

Press: 4 mainstream 45 specialist 16 independent outlet-days

What it is

Evidence 7/10 · established for some uses Uneven · 2–8 by use Signals · regulator warning

Gene therapy treats disease by adding, editing or silencing genes, usually delivered by a modified virus, and now includes CRISPR-based editing. It is in the news because of approved treatments for spinal muscular atrophy, sickle cell disease, haemophilia and inherited blindness at prices up to several million dollars, and because long-feared risks are materialising: in November 2026 Novartis reported tumours in children treated with Zolgensma. The science has delivered real cures for some single-gene diseases; durability, safety and cost remain open questions, and each product must be judged on its own trial record.

The score describes approved gene therapies for single-gene diseases such as spinal muscular atrophy and sickle cell disease. Most of the field, including therapies for common diseases, remains experimental, and long-term safety is still being measured.

Evidence by use or claim · 1 preclinical to 10 thoroughly established

  1. Spinal muscular atrophy (Zolgensma)8/10 · established for some uses

    approved 2019, large survival benefit, new tumour reports under review

  2. Inherited retinal dystrophy (Luxturna)8/10 · established for some uses

    approved 2017

  3. Sickle cell disease and beta thalassaemia (Casgevy, Lyfgenia)7/10 · established for some uses

    approved 2023, short follow-up

  4. Haemophilia7/10 · established for some uses

    approved, durability varies

  5. Duchenne muscular dystrophy (Elevidys)5/10 · mixed or limited trials

    accelerated approval, failed confirmatory endpoint, deaths in 2025

  6. Common diseases such as heart failure or Parkinson's2/10 · preclinical

    early trials only

  • RegulatorIn November 2026 the FDA opened an investigation after Novartis reported nine tumour cases in children treated with the AAV-based therapy Zolgensma.
  • RegulatorIn 2025 the FDA asked Sarepta to pause shipments of the Duchenne therapy Elevidys after patient deaths from acute liver failure.
  • MechanismViral vectors that integrate into the genome can disrupt genes that control cell growth; leukaemia cases in early SCID-X1 trials in the 2000s established the risk of insertional mutagenesis.
  • MarketApproved products cost between about 2 and 4 million dollars per patient, and several have been withdrawn in Europe for commercial rather than safety reasons.

This week · Novartis reported nine cases of tumours in children treated with its gene therapy Zolgensma, and the FDA said it is investigating whether the viral vector is responsible.

Written by the Alivewire editors from the coverage below, 1d ago; rated 1d ago. Not medical advice; how the ratings work.

Coverage